ATE517183T1 - Monoklonaler antikörper gegen cd20 - Google Patents

Monoklonaler antikörper gegen cd20

Info

Publication number
ATE517183T1
ATE517183T1 AT09011119T AT09011119T ATE517183T1 AT E517183 T1 ATE517183 T1 AT E517183T1 AT 09011119 T AT09011119 T AT 09011119T AT 09011119 T AT09011119 T AT 09011119T AT E517183 T1 ATE517183 T1 AT E517183T1
Authority
AT
Austria
Prior art keywords
monoclonal antibody
monoclonal antibodies
antibodies against
antigen
cell
Prior art date
Application number
AT09011119T
Other languages
English (en)
Inventor
Masanori Numazaki
Tetsuo Nakamura
Sadakazu Usuda
Eduardo A Padlan
Original Assignee
Biomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37073509&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE517183(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biomedics Inc filed Critical Biomedics Inc
Application granted granted Critical
Publication of ATE517183T1 publication Critical patent/ATE517183T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
AT09011119T 2005-03-31 2006-03-31 Monoklonaler antikörper gegen cd20 ATE517183T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005103093 2005-03-31
JP2005378466 2005-12-28

Publications (1)

Publication Number Publication Date
ATE517183T1 true ATE517183T1 (de) 2011-08-15

Family

ID=37073509

Family Applications (2)

Application Number Title Priority Date Filing Date
AT09011119T ATE517183T1 (de) 2005-03-31 2006-03-31 Monoklonaler antikörper gegen cd20
AT06730873T ATE495248T1 (de) 2005-03-31 2006-03-31 Monoklonaler anti-cd20-antikörper

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT06730873T ATE495248T1 (de) 2005-03-31 2006-03-31 Monoklonaler anti-cd20-antikörper

Country Status (17)

Country Link
US (1) US8101179B2 (de)
EP (2) EP1865058B1 (de)
JP (1) JP4813465B2 (de)
KR (1) KR101188117B1 (de)
CN (1) CN101870730A (de)
AT (2) ATE517183T1 (de)
AU (2) AU2006231784B2 (de)
BR (1) BRPI0609543B1 (de)
CA (1) CA2603414C (de)
DE (1) DE602006019565D1 (de)
DK (1) DK2143795T3 (de)
IL (2) IL186387A (de)
MX (1) MX2007012197A (de)
PL (1) PL2143795T3 (de)
RU (1) RU2415871C2 (de)
TW (1) TWI381050B (de)
WO (1) WO2006106959A1 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2096166A1 (de) * 2005-03-31 2009-09-02 Osaka University Verfahren zur Herstellung von gegen das Zellmembranoberflächen-Antigenepitop gerichteten Antikörpern und Assay-Verfahren
WO2007102200A1 (ja) * 2006-03-07 2007-09-13 Osaka University 抗ｃｄ２０モノクローナル抗体
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
EP2318832B1 (de) 2008-07-15 2013-10-09 Academia Sinica Glycan-arrays auf objektträgern mit ptfe-aluminiumbeschichtung und entsprechende verfahren
TW201438738A (zh) 2008-09-16 2014-10-16 建南德克公司 治療進展型多發性硬化症之方法
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
US8815242B2 (en) 2009-05-27 2014-08-26 Synageva Biopharma Corp. Avian derived antibodies
RU2595409C2 (ru) 2009-09-03 2016-08-27 Мерк Шарп И Доум Корп., Анти-gitr-антитела
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
CN103068378B (zh) 2010-05-10 2016-07-06 中央研究院 具有抗流感活性的扎那米韦膦酸酯同类物及其制备方法
JP2013541501A (ja) 2010-08-03 2013-11-14 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 慢性リンパ性白血病（ｃｌｌ）のバイオマーカー
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
CN103033621B (zh) * 2011-10-09 2016-01-20 嘉和生物药业有限公司 一种抗cd20单克隆抗体结合活性的检测方法
WO2013088363A1 (en) * 2011-12-13 2013-06-20 Nordic Nanovector As Chimeric therapeutic anti - cd37 antibodie hh1
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
JP6302909B2 (ja) 2012-08-18 2018-03-28 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ シアリダーゼの同定および画像化のための細胞透過性プローブ
US9547009B2 (en) 2012-08-21 2017-01-17 Academia Sinica Benzocyclooctyne compounds and uses thereof
US9758591B2 (en) 2012-08-24 2017-09-12 The Regents Of The University Of California Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
MX368286B (es) 2013-04-17 2019-09-27 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
AU2014254056B2 (en) 2013-04-17 2019-06-06 Signal Pharmaceuticals, Llc Combination therapy comprising a TOR kinase inhibitor and an IMiD compound for treating cancer
CN105339008A (zh) 2013-04-17 2016-02-17 西格诺药品有限公司 用于治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯酰胺的组合疗法
WO2014179661A1 (en) 2013-05-03 2014-11-06 Celgene Corporation Methods for treating cancer using combination therapy
US10086054B2 (en) 2013-06-26 2018-10-02 Academia Sinica RM2 antigens and use thereof
WO2014210564A1 (en) 2013-06-27 2014-12-31 Academia Sinica Glycan conjugates and use thereof
CA2923579C (en) 2013-09-06 2023-09-05 Academia Sinica Human inkt cell activation using glycolipids with altered glycosyl groups
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
US9982041B2 (en) 2014-01-16 2018-05-29 Academia Sinica Compositions and methods for treatment and detection of cancers
CN106415244B (zh) 2014-03-27 2020-04-24 中央研究院 反应性标记化合物及其用途
CN106661099A (zh) 2014-05-27 2017-05-10 中央研究院 抗her2醣抗体及其用途
US20150344585A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-cd20 glycoantibodies and uses thereof
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
EP3904388A1 (de) 2014-05-27 2021-11-03 Academia Sinica Fucosidase aus bacteroiden und verfahren damit
EP3154582A4 (de) 2014-05-28 2018-01-10 Academia Sinica Anti-tnf-alpha-glycoantikörper und verwendungen davon
EP3191500A4 (de) 2014-09-08 2018-04-11 Academia Sinica Aktivierung menschlicher inkt-zellen mithilfe von glykolipiden
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
CA2972072A1 (en) 2015-01-24 2016-07-28 Academia Sinica Novel glycan conjugates and methods of use thereof
JP6771492B2 (ja) 2015-05-30 2020-10-21 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. 脱免疫化された志賀毒素ａサブユニット足場及びそれを含む細胞標的化分子
KR20180114210A (ko) 2016-03-08 2018-10-17 아카데미아 시니카 N-글리칸의 모듈 합성 방법 및 그의 어레이
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
MX2018016330A (es) 2016-06-27 2020-02-17 Univ California Combinaciones para tratamiento del cáncer.
US20190330318A1 (en) 2016-07-25 2019-10-31 Biogen Ma Inc. Anti-hspa5 (grp78) antibodies and uses thereof
US10538592B2 (en) 2016-08-22 2020-01-21 Cho Pharma, Inc. Antibodies, binding fragments, and methods of use
CA3046489A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018162724A1 (en) * 2017-03-09 2018-09-13 Mab Discovery Gmbh Antibodies specifically binding to human il-1r7
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
CN112566936B (zh) 2018-08-21 2024-07-12 阿尔伯特爱因斯坦医学院 针对人tim-3的单克隆抗体
US12460000B2 (en) 2018-09-07 2025-11-04 Itabmed (Hk) Limited Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
CN116726361A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
US11345744B2 (en) 2019-05-07 2022-05-31 William R Church Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN111808191A (zh) * 2020-05-11 2020-10-23 廊坊天光生物技术有限公司 一种用于检测血清中vegf含量的抗体对及其用途
WO2022019924A1 (en) * 2020-07-23 2022-01-27 Church William R Antibody specific to staphylococcus aureus, therapeutic method and detection method using same
JP7057954B2 (ja) * 2020-09-03 2022-04-21 国立大学法人大阪大学 改善された保存安定性を有するタンパク質含有液体製剤
AU2021357841A1 (en) 2020-10-08 2023-06-15 Affimed Gmbh Trispecific binders
JP2024529381A (ja) 2021-07-30 2024-08-06 アフィメド ゲーエムベーハー デュプレックスボディ
KR20240099382A (ko) 2021-11-03 2024-06-28 아피메트 게엠베하 이중특이적 cd16a 결합제
CN114773474B (zh) * 2022-05-20 2023-05-16 赛尔托马斯生物科技(成都)有限公司 Nk细胞的制备方法及其抗癌的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1005870B1 (de) * 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierungs-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyten beschränkt ist, für die Behandlung von B-Zell-Lymphoma
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
JP3582965B2 (ja) 1996-08-23 2004-10-27 株式会社イムノ・ジャパン 哺乳動物細胞用発現ベクター
JP2001074737A (ja) 1999-09-03 2001-03-23 Asahi Breweries Ltd 抗ヒトＩｇＥモノクローナル抗体
EP2295064B1 (de) 2001-03-15 2017-02-22 Precision Biologics, Inc. Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
CA2476166C (en) 2002-02-14 2011-11-15 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
WO2005000901A2 (en) 2003-05-09 2005-01-06 Duke University Cd20-specific antibodies and methods of employing same
EP2236172A1 (de) * 2003-11-04 2010-10-06 Novartis Vaccines and Diagnostics, Inc. Kombinationstherapie mit anti-CD20 und anti-CD40 Antikörper zur Behandlung von B-Zell Krebsarten
WO2007102200A1 (ja) * 2006-03-07 2007-09-13 Osaka University 抗ｃｄ２０モノクローナル抗体

Also Published As

Publication number Publication date
RU2415871C2 (ru) 2011-04-10
CA2603414A1 (en) 2006-10-12
CA2603414C (en) 2012-09-18
IL186387A (en) 2011-03-31
US8101179B2 (en) 2012-01-24
JPWO2006106959A1 (ja) 2008-09-18
EP2143795B1 (de) 2011-07-20
TWI381050B (zh) 2013-01-01
AU2006231784B2 (en) 2010-10-14
AU2006231784A1 (en) 2006-10-12
EP1865058A1 (de) 2007-12-12
US20090197330A1 (en) 2009-08-06
IL186387A0 (en) 2008-01-20
HK1138621A1 (en) 2010-08-27
DE602006019565D1 (de) 2011-02-24
EP2143795A3 (de) 2010-02-24
AU2010214745B2 (en) 2011-12-15
KR20070116175A (ko) 2007-12-06
TW200714711A (en) 2007-04-16
AU2010214745A1 (en) 2010-09-23
KR101188117B1 (ko) 2012-10-09
PL2143795T3 (pl) 2011-12-30
BRPI0609543A2 (pt) 2011-10-18
EP1865058B1 (de) 2011-01-12
DK2143795T3 (da) 2011-09-19
BRPI0609543B1 (pt) 2021-11-09
HK1111728A1 (en) 2008-08-15
RU2007140257A (ru) 2009-05-10
JP4813465B2 (ja) 2011-11-09
WO2006106959A1 (ja) 2006-10-12
EP1865058A4 (de) 2009-03-25
MX2007012197A (es) 2007-11-21
ATE495248T1 (de) 2011-01-15
CN101870730A (zh) 2010-10-27
IL206783A (en) 2012-03-29
EP2143795A2 (de) 2010-01-13

Similar Documents

Publication Publication Date Title
ATE517183T1 (de) Monoklonaler antikörper gegen cd20
NL301196I2 (nl) inebilizumab
EP1885399A4 (de) Humanisierte antikörper gegen cd40 und verfahren zu ihrer anwendung
SI1810026T1 (en) B7-h1 and pd-1 in treatment of renal cell carcinoma
ATE505544T1 (de) Monoklonale antikörper und einzelkettenantikörper fragments gegen das zelloberflächen prostataspezifische membranantigen
NO20071436L (no) Humaniserte Anti-5T4 antistoffer og Anti-5T4 antistoff/calicheamicin konjugater
DK1565489T3 (da) Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet
BRPI0811526A2 (pt) uso de um anticorpo monoclonal, quimérico, humanizado ou humano que liga o il-5r, anticorpo anti-il-5r isolado, e, epítopo isolado de il-5r alfa
WO2006099141A3 (en) Anti-mesothelin antibodies
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
DK1684805T3 (da) Anvendelse af antagonist anti-CD40-monoklonale antistoffer til behandling af multipel myeloma
DK1641828T3 (da) Anti-HGF-R-antistoffer og deres anvendelse
EA200700083A1 (ru) Антитела, направленные против бета-амилоидного пептида, и способы их применения
ATE549358T1 (de) Neuer anti-plgf-antikörper
TW200639182A (en) Antibody variants and uses thereof
CR20120587A (es) Moléculas de unión al antígeno que fijan egfr, vectores que las codifican y uso de las mismas
EP1485130A4 (de) Reagenzien und behandlungsverfahren für autoimmunkrankheiten
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
DK2070948T3 (da) Humant Anti-CD4-antistof med immunsuppressive egenskaber
RU2406730C2 (ru) Гуманизированное моноклональное анти-cd20-антитело
WO2007087289A3 (en) Anti-fcrn antibodies for treatement of auto/allo immune conditions
WO2008146165A3 (en) Kit of parts for the treatment of cancer or infectious diseases
MX2022012182A (es) Metodos de uso de anticuerpos anti-trem2.
ATE517340T1 (de) Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren
WO2006004950A3 (en) Humanized monoclonal antibody 31.1 as an anticancer agent

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2143795

Country of ref document: EP